ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)
Urinary C-peptide to creatinine ratio (UCPCR) as indicator for metabolic risk in apparently healthy adults - a BioPersMed cohort study
Sharmaine Reintar 1 , Magdalena Pöchhacker 2 , Anna Obermayer 1 , Katharina Eberhard 3 , Andreas Zirlik 4 , Nicolas Verheyen 4 , Christoph Haudum 1 , Thomas Pieber 1 , Harald Sourij 1 & Barbara Obermayer-Pietsch 1
1Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology and Endocrinology Lab Platform, Austria; 2University of Vienna, Austria, Department of Food Chemistry and Toxicology, Faculty of Chemistry, Austria; 3Medical University of Graz, Center for Medical Research, Core Facility Computational Bioanalytics, Austria; 4Medical University of Graz, Department of Internal Medicine, Division of Cardiology, Austria
Background: C-peptide consists of 31 amino acids, synthesized in the beta cells of the pancreas and co-secreted along with insulin. Hence, serum C-peptide may be the preferred diagnostic biomarker for evaluating beta cell function compared to insulin. The urinary C-peptide to creatinine ratio (UCPCR) recently gained attention as a non-invasive biomarker for evaluating and monitoring metabolic risk. In this study, we aimed to characterize guiding values of UCPCR in healthy individuals based on American Diabetes Association (ADA) criteria and follow-up outcomes in a large longitudinal cohort study.
Methods: Cross-sectional and longitudinal clinical and laboratory phenotyping including body composition and oral glucose tolerance tests of participants from the BioPersMed cohort (Biomarkers in Personalized Medicine) were evaluated. Our study population was based on ADA (American Diabetes Association) criteria defining non-diabetic subjects via fasting plasma glucose (FPG) ≤ 126 mg/ml (≤ 7.0 mmol/l), 2-hour plasma glucose (2-h PG) of ≤ 200 mg/dl (≤ 11.1 mmol/l) during 75-g oral glucose tolerance test (oGTT), and an HbA1c of ≤ 6.5% (≤ 48mmol/mol). A two-site chemiluminescent sandwich immunoassay was used to detect urinary C-peptide levels, which were normalized by individual urinary creatinine values to obtain the ratio. Subjects were followed for 4.2±0.62 years from baseline to their first and second biannual follow-up.
Results: Out of all BioPersMed participants (n=1022), 317 individuals were non-diabetic according to ADA criteria (female n=198 (62,5%), male n=119 (37,5%)) with a median age of 56±8 years. In our study, we found no significant differences of UCPCR values between gender (P-value 0,997). During follow-up, initially healthy participants progressed by 25% to prediabetes and by 1% to type 2 diabetes mellitus (T2DM), predicted by UCPCR values.
Conclusion: UCPCR provides a valuable diagnostic biomarker for a non-invasive estimation of endogenous insulin production, which can be used to monitor and guide individual subjects over time for their potentially increased metabolic risk. A risk assessment graph for UCPCR ranges provides a useful screening and monitoring tool. UCPCR applications are not limited to T2DM but could further be used in other settings such as hyperinsulinemia in obesity or polycystic ovary syndrome (PCOS) and gestational diabetes
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more